FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis
Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and the quality of life benefits that avapritinib provides for patients in this population.
United States Stanford University Jason Gotlib Ashling Wahner Stanford Cancer Institute Apple Podcasts
Source: onclive.com